Synthesis and biological evaluation of new 4-thiazolidinone derivatives

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 4, 2009, Pages 1015-1023

  Güzel, Özlen ^a   Salman, Aydin ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antimycobacterial activity; Antitumor activity; Thiazolidinone

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; THIAZOLIDINE DERIVATIVE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; FEMALE; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NEOPLASM; SYNTHESIS; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; NEOPLASMS; THIAZOLIDINES;

EID: 76249130144     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802608021     Document Type: Article

References (29)

1. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC.(1999). Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. J Am Med Assoc, 282, 677-686.
2. Bass JB, Farer LS, Hopewell PC, O'Brein R, Jacob RF, Ruben F, Snider DE Jr, Thornton G.(1994). Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and the Centers for Disease Control and Prevention. Am J Respir Crit Care Med,149, 1359-1374.
3. Farmer P, Bayona J, Becerra M, Furin J, Henry C, Hiatt H, Kim JY, Mitnick C, Nardell E, Shin S.(1998). The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis, 2, 869-876.
4. World Health Organization. (2000). Anti-Tuberculosis Drug Resistance in the World-Report No. 2. Prevalence and Trends. Geneva, Switzerland: WHO.
5. Ginsburg AS, Grosset JH, Bishai WR.(2003). Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis, 3, 432-442.
6. Alland D, Kalkut GE, Moss AR, McAdam RA, Hahn JA, Bosworth W, Drucker E, Bloom BR.(1994). Transmission of tuberculosis in New York city - an analysis by DNA fingerprinting and conventional epidemiologic methods. N Engl J Med, 330, 1710-1716.
7. Ulusoy N.(2002). Synthesis and antituberculosis activity of cycloalkylidenehydrazide and 4-aza-1-thiaspiro[4,5]decan-3-one derivatives of imidazo[2,1-b]thiazole. Arzneim-Forsch/Drug Res, 52, 565-571.
8. Srivastava T, Gaikwad AK, Haq W, Sinha S, Kati SB.(2005). Synthesis and biological evaluation of 4-thiazolidinone derivatives as potential antimycobacterial agents. Arkivoc, ii, 120-130.
9. Bukowski L, Janowiec M, Zwolska-Kwiek Z, Andrezejczyk Z.(1998). Some reactions of 2-cyanomethylimidazo[4,5-b]pyridine with isothiocyanates. Antituberculotic activity of the obtained compounds. Pharmazie, 53, 373-376.
10. Babaoglu K, Page MA, Jones VC, McNeil MR, Dong C, Naismith JH, Lee RE.(2003). Novel inhibitors of an emerging target in Mycobacterium tuberculosis; substituted thiazolidinones as inhibitors of dTDP-rhamnose synthesis. Bioorg Med Chem Lett, 13, 3227-3230.
11. Çapan G, Ulusoy N, Ergenç N, Kiraz M.(1999). New 6-phenylimidazo[2,1-b] thiazole derivatives: synthesis and antifungal activity. Monatsh Chem, 130, 1399-1407.
12. Karali N, Ilhan E, Gürsoy A, Kiraz M.(1998). New cyclohexlidenehydrazide and 4-aza-1-thiaspiro[4,5]decan-3-one derivatives of 3-phenyl-4(3H)- quinazolinones. Farmaco, 53, 346-349.
13. Fahmy HTY.(2001). Synthesis of some new triazoles as potential antifungal agents. Boll Chim Farmaco, 140, 422-427.
14. Barreca ML, Chimirri A, Luca LD, Monforte AM, Monforte P, Rao M, Zappalá M, Balzarini J, De Clercq E, Pannecouque C, Witvrouw P.(2001). Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. Bioorg Med Chem Lett, 11, 1793-1796.
15. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalá M.(2002). Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-(thi)one derivatives. Farmaco, 57, 747-751.
16. Rao A, Carbone A, Chimirri A, De Clercq E, Monforte AM, Monforte P, Pannecouque C, Zappalá M.(2003). Synthesis and anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones. Farmaco, 58, 115-120.
17. Barreca ML, Chimirri A, De Clercq E, Luca LD, Monforte AM, Monforte P, Rao A, Zappalá M.(2003). Design and discovery of new potent RT inhibitors. Farmaco, 58, 259-263.
18. Rao A, Balzarini J, Carbone A, Chimirri A, De Clercq E, Luca LD, Monforte AM, Monforte P, Pannecouque C, Zappalá M.(2004). Synthesis of new 2,3- diaryl-1,3-thiazolidin-4-ones as anti-HIV agents. Farmaco, 59, 33-39.
19. Ragab FA, Eid NM, El-Tawab HA.(1997). Synthesis and anticonvulsant activity of new thiazolidinone and thioxoimidazolidinone derivatives derived from furochromones. Pharmazie, 52, 926-929.
20. Kaynak FB, Öztürk D, Özbey S, Çapan G.(2005). New N'-alkylidene/ cycloalkylidene derivatives of 5-methyl-3-phenyl-1H-indole-2- carbohydrazide: synthesis, crystal structure, and quantum mechanical calculations. J Mol Struct, 740, 213-221.
21. Bicking JB, Bock MG, Cragoe EJ, Dipardo RM, Gould NP, Holltz WJ, Lee TJ, Robb CM, Smith RL, Springer JP, Blaine EH. (1983). Prostaglandin isosteres. 2. Chain-modified thiazolidinone prostaglandin analogs as renal vasodilators. J Med Chem, 26, 342-348.
22. Güzel Ö, Ilhan E, Salman A.(2006). Synthesis and antimycobacterial activity of new 2-hydroxy-N-(3-oxo-1-thia-4-azaspiro[4.4]non- 4- yl)/(3-oxo-1-thia-4-azaspiro-[4.5]dec-4-yl)-2,2-diphenylacetamide derivatives. Monatsh Chem, 137, 795-801.
23. Karali N, Ilhan E, Gürsoy A, Kiraz M.(1998). New cyclohexylidenhydrazide and 4-aza-1-thiaspiro[4,5]decan-3-one derivatives of 3-phenyl-4-(3H)- quinazolinones. Farmaco, 52, 1-5.
24. Peter R, Hellenbrand J, Mengerink Y, Van der Wal Sj J.(2004). On-line determination of carboxylic acids, aldehydes and ketones by highperformance liquid chromatography-diode array detection-atmospheric pressure chemical ionisation mass spectrometry after derivatization with 2-nitrophenylhydrazine. Chromatogr A, 1031, 35-50.
25. Çapan G, Ulusoy N, Ergenç N, Ekinci AC, Vidin A.(1996). Synthesis and anticonvulsant activity of new 3-[(2-furyl)carbonyl]amino- 4-thiazolidinone and 2-[(furyl)carbonyl]hydrazono-4-thiazoline derivatives. Farmaco, 51, 729-732.
26. Collins LA, Franzblau SG. (1997). Microplate Alamar Blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob Agents Chemother, 41, 1004-1009.
27. Alley MC, Scudiero DA, Monks PA, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR.(1988). Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res, 48, 589-601.
28. Grever MR, Schepartz SA, Chabner BA.(1992). The National Cancer Institute: Cancer Drug Discovery and Development Program. Semin Oncol, 19(6), 622.
29. Boyd MR, Paull KD.(1995). Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Devel Res, 34, 91-109.